An anti-allergic and soothing composition, its preparation method and application

Abstract

This invention belongs to the field of skincare products, specifically relating to an anti-allergic and soothing composition, its preparation method, and its application. The anti-allergic and soothing composition comprises: Phase A, including water, a chelating agent, and a thickener; Phase B, including sodium hyaluronate and 1,3-butanediol; Phase C, including arginine; Phase D, including p-hydroxyacetophenone and 1,3-butanediol; and Phase E, including a moisturizer, a soothing and anti-inflammatory factor, and a preservative. The soothing and anti-inflammatory factor comprises at least three of the following: oat extract, gardenia fruit extract, hydrolyzed corn starch, kava root extract, and dragon's blood extract. These five substances can all exert anti-inflammatory effects through multiple mechanisms, and the combination of three of them allows the soothing and anti-inflammatory factor to achieve anti-inflammatory effects through multiple dimensions and different mechanisms.

Description

Technical Field

[0001] This invention relates to the field of skincare products, and in particular to an anti-allergic and soothing composition, its preparation method, and its application. Background Technology

[0002] Currently, various skincare products with different functions are available on the market to suit different skin types, among which anti-allergy and soothing skincare products are mainly aimed at people with sensitive skin. According to the "Chinese Expert Consensus on the Diagnosis and Treatment of Sensitive Skin," sensitive skin specifically refers to a hyperreactive state of the skin under physiological or pathological conditions, most commonly seen on the face. Clinically, it manifests as subjective symptoms such as burning, stinging, itching, and tightness when stimulated by physical, chemical, or psychological factors, with or without objective signs such as erythema, scaling, and telangiectasia. Essentially, it is a state of hyperresponsiveness of the neurosensory and immune systems following damage to the skin's physiological structure (especially the epidermal barrier function). It is not an independent disease, but rather a sub-healthy, hyperreactive manifestation of the skin. In recent years, influenced by unhealthy lifestyles and high-pressure psychological states, consumer demand for anti-allergy and soothing skincare products has continued to grow, and the requirements for product efficacy have also gradually increased.

[0003] Existing anti-allergy and soothing skincare products mostly achieve their effects by adding ingredients with one or more functions such as barrier repair, anti-inflammation, and moisturizing and stabilizing. Among these, anti-inflammatory ingredients are key to their anti-allergy effect. However, in practice, most products are only effective for some consumers, while having no significant soothing effect on others. The core reason for this phenomenon is that the mechanisms triggering sensitive skin are diverse, and the core ingredients in existing products are often designed for only a single anti-inflammatory mechanism, making it difficult to accurately match the different sensitivity triggers of different consumers.

[0004] To broaden the reach of anti-allergy and soothing skincare products to a wider consumer base, the key lies in ensuring that the product's core anti-inflammatory ingredients achieve their anti-inflammatory effects through multiple dimensions and different mechanisms, creating a synergistic effect. Currently, the industry still lacks such anti-allergy and soothing skincare products with multi-mechanism synergistic anti-inflammatory properties, making it difficult to meet consumers' demand for highly effective and universally applicable anti-allergy products. Summary of the Invention

[0005] Based on this, the purpose of the present invention is to overcome the defects or deficiencies of the prior art and provide an anti-allergic and soothing composition to solve the technical problem that existing anti-allergic and soothing skin care products cannot achieve anti-inflammatory effects through multiple dimensions and different mechanisms.

[0006] An anti-allergic and soothing composition comprising:

[0007] Phase A includes water, chelating agents, and thickeners;

[0008] Phase B includes sodium hyaluronate and 1,3-butanediol;

[0009] Phase C includes arginine;

[0010] Phase D includes p-hydroxyacetophenone and 1,3-butanediol;

[0011] Phase E includes moisturizers, soothing and anti-inflammatory factors, and preservatives;

[0012] The soothing and anti-inflammatory factors include at least three of the following: oat extract, gardenia fruit extract, hydrolyzed corn starch, kava root extract, and dragon's blood extract. All five substances exert anti-inflammatory effects through multiple mechanisms, and the combination of three of them allows the soothing and anti-inflammatory factors to achieve their anti-inflammatory effects through multiple dimensions and different mechanisms.

[0013] In one embodiment, the soothing and anti-inflammatory factor includes oat extract, gardenia fruit extract, and hydrolyzed corn starch; wherein the volume fractions of the oat extract, gardenia fruit extract, and hydrolyzed corn starch in the soothing and anti-inflammatory factor are 5-20 parts, 5-20 parts, and 5-20 parts, respectively.

[0014] In one embodiment, the method for preparing the oat extract includes: taking oat flour, extracting it in a solvent at 45-55°C for 1.5-3 hours, centrifuging, ultrafiltration, and concentration to obtain the oat extract, wherein the solvent is water, a mixture of water and glycerol, or a mixture of water and butylene glycol.

[0015] In one embodiment, the preparation method of the gardenia fruit extract includes: crushing gardenia fruit, adding 10-15 times the volume of water, ultrasonically extracting at 50-70℃ for 30-60 minutes, filtering, and concentrating to obtain the gardenia fruit extract.

[0016] In one embodiment, the method for preparing the hydrolyzed corn starch includes: sequentially hydrolyzing corn starch with a heat-resistant α-amylase and a saccharifying enzyme, followed by heating to inactivate the enzymes, decolorizing, and filtering to obtain the hydrolyzed corn starch.

[0017] In one embodiment, the chelating agent of phase A includes EDTA-2Na; the thickening agent of phase A includes Carbomer 941; and the humectant of phase E includes glyceryl glucoside.

[0018] In one embodiment, the anti-allergic and soothing composition, by volume parts:

[0019] Phase A consists of 80-90 parts water, 0.01-0.05 parts EDTA-2Na, and 0.1-0.4 parts Carbopol 941;

[0020] Phase B includes 0.01-0.1 parts sodium hyaluronate and 2-4 parts 1,3-butanediol;

[0021] Phase C includes 0.1-0.4 parts of arginine;

[0022] Phase D includes 0.1-0.4 parts of p-hydroxyacetophenone and 1-3 parts of 1,3-butanediol;

[0023] Phase E includes 0.5-1.5 parts glycerol glucoside, 3-7 parts soothing and anti-inflammatory factors, and 0.5-1.5 parts preservatives.

[0024] The present invention also provides a method for preparing an anti-allergic and soothing composition, comprising the following steps:

[0025] S1. Heat phase A to 80-85℃ and stir to dissolve;

[0026] S2. After phase A cools down to 55°C, add the well dispersed phase B to phase A and stir until homogeneous.

[0027] S3. Add phase C to the mixture from step S2 and stir until homogeneous;

[0028] S4. Heat phase D to 50°C, stir to dissolve, and then add it to the mixture from step S3, stirring.

[0029] S5. After the mixture from step S4 has cooled to 41-43℃, add the raw materials of phase E in sequence and stir evenly.

[0030] The present invention also provides an application of an anti-allergic and soothing composition in the preparation of skin care products.

[0031] In one embodiment, the skincare products include toners, skincare gels, skincare lotions, skincare creams, serums, face masks, and sprays.

[0032] To better understand and implement this invention, the following detailed description is provided in conjunction with the accompanying drawings. Attached Figure Description

[0033] Figure 1 The graph shows the inhibition rate of hyaluronidase activity for combinations 1-10.

[0034] Figure 2 The graph shows the inhibition rate of hyaluronidase activity by combinations 11-19.

[0035] Figure 3 The effect of soothing anti-inflammatory factors on the levels of three inflammatory factors is shown in the figure.

[0036] Figure 4 The graph shows the downregulation rate of the levels of three inflammatory factors by soothing and anti-inflammatory factors.

[0037] Figure 5 The graph shows the relative content and relative inhibition rate of the inflammatory mediator NO by the soothing and anti-inflammatory factors.

[0038] Figure 6The image shows the test results of the anti-inflammatory factors in humans, which have the effects of reducing redness and relieving itching.

[0039] Figure 7 The image shows the test results of the anti-allergic effect of the soothing and anti-inflammatory factors on the human body.

[0040] Figure 8 This is a graph showing the efficacy test results of an anti-allergic and soothing composition containing calming and anti-inflammatory factors. Detailed Implementation

[0041] This invention first optimizes the core ingredient of anti-inflammatory skincare products, which primarily exerts its anti-inflammatory effect, enabling it to achieve anti-inflammatory properties through multiple mechanisms. In this invention, this core ingredient is referred to as the soothing anti-inflammatory factor.

[0042] First, this invention selects five plant-derived anti-allergic components (oat extract, gardenia fruit extract, hydrolyzed corn starch, kava root extract, and dragon's blood extract), and arranges three of them into groups for combination. Butylene glycol, hexanediol, and water are added as excipients and solvents to form a total of 10 combinations. The combinations 1-10 and the volume ratios of each component are shown in Table 1. Subsequently, by detecting the inhibition rate of hyaluronidase activity by combinations 1-10, the component of the combination with the best soothing effect is selected as the soothing and anti-inflammatory factor.

[0043] Table 1. Combination of Candidate Soothing and Anti-inflammatory Factors

[0044]

[0045] The preparation method of oat extract is as follows.

[0046] To maximize the extraction of water-soluble active ingredients while ensuring the final product is free of solvent residue, water, a mixture of water and glycerol (5%-20% glycerol concentration), or a mixture of water and butylene glycol are used as solvents. Oat flour is gently extracted for 1.5-3 hours under precisely controlled low temperature (45-55°C) and weakly alkaline conditions (pH 7.5-8.5) at a feed-to-liquid ratio of 1:8 to 1:15. The extract is then centrifuged, ultrafiltered (molecular weight cutoff 5-50 kDa), and concentrated under vacuum at low temperature (≤60°C) to a soluble solids content of 15%-30% Brix, yielding a standardized oat extract.

[0047] The preparation method of gardenia fruit extract is as follows.

[0048] First, in the pretreatment stage, the gardenia fruit raw material needs to be purified and pulverized to a uniform particle size of 20-40 mesh to significantly increase its contact area with the solvent and improve subsequent extraction efficiency. Then, in the extraction stage, purified water is used as the solvent, and extraction is performed for 30-60 minutes using ultrasonic enhancement at a power density of 0.3-0.8 W / mL and a temperature of 50-70℃, under a material-to-liquid ratio of 1:10 to 1:15. The obtained extract needs to be coarsely filtered to remove physical impurities, and then concentrated at low temperature using nanofiltration or vacuum concentration to a paste with a solid content of 30%-50%. Finally, this concentrated paste is instantaneously dried using spray drying technology. By precisely controlling parameters such as the inlet air temperature of 160-190℃ and the outlet air temperature of 80-100℃, the final product is the gardenia fruit extract powder.

[0049] The preparation method of hydrolyzed corn starch is as follows.

[0050] Prepare a 30-35% corn starch slurry and adjust the pH to 5.8-6.2. Add heat-resistant α-amylase (0.5-0.6 L / ton of dry starch), spray the solution at 105-110℃, and then incubate at 95-97℃ for 1-1.5 hours to randomly cleave the starch chains, obtaining a liquefied solution with a DE value of 12-18%. Cool the liquefied solution to 60℃ and adjust the pH to 4.0-4.5. Add saccharifying enzyme (1.0-1.2 L / ton of dry starch) and incubate for 48-72 hours. After saccharification, heat to 80-85℃ to inactivate the enzyme, and then refine the solution through decolorization, filtration, and ion exchange to obtain the hydrolyzed corn starch product.

[0051] The preparation method of the dragon's blood extract is as follows.

[0052] First, the raw materials are pretreated by crushing the lumpy resin and passing it through a 20-40 mesh sieve to obtain a uniform powder. Then, the raw material and pure water are added to an extraction tank at a material-to-liquid ratio of 1:10 to 1:15 (g / mL), and soaked at room temperature for 1-2 hours to allow the material to fully swell. The extraction stage uses a decoction method, heating to 90-100°C and maintaining a gentle boil. Each extraction lasts 1.5-2 hours, and this process is repeated 2-3 times to fully extract the water-soluble components. After extraction, the extracts are combined while hot (>60°C) and sequentially passed through a 100-mesh sieve and a plate and frame filter press for solid-liquid separation to obtain a clear filtrate. The obtained filtrate is then further purified by centrifugation or fine filtration to remove insoluble impurities. The pre-purified filtrate is then transferred to a concentration device for vacuum concentration until the soluble solids content (measured by a refractometer, Brix) reaches 20-30%, in order to recover some water and obtain a high-concentration dragon's blood extract solution.

[0053] The preparation method of kava pepper root extract is as follows.

[0054] Kava root extract was prepared by supercritical CO2 extraction. First, the dried rhizomes of kava were pulverized to increase their specific surface area, thereby improving subsequent extraction efficiency. Then, the raw material was loaded into an extraction vessel and the system was sealed. Liquid CO2 was injected through a high-pressure pump, and the system was heated to a supercritical state. At a pressure of 25-35 MPa and a temperature of 40-60°C, supercritical CO2 fluid was allowed to permeate into the raw material. The raw material was then extracted using supercritical CO2 fluid circulation for 2-4 hours, efficiently dissolving lipophilic active components such as kavalactone. By gradually reducing the pressure and temperature (e.g., reducing the pressure to 5-8 MPa in the first stage), kavalactone precipitated in the separation vessel, yielding a high-purity resinous extract. The precipitated CO2 gas was condensed and recovered and could be recycled back into the extraction process. The entire process was carried out in a low-temperature, light-protected environment free of organic solvent residues, effectively protecting heat-sensitive components and ensuring the safety and purity of the final product.

[0055] All five substances have anti-inflammatory effects through various mechanisms. Therefore, combining any three of them can provide as many soothing and anti-inflammatory factors with multidimensional anti-inflammatory mechanisms as possible.

[0056] Specifically, the main active ingredients in oat extract include β-glucan, phenolic compounds (phenolic acids, flavonoids), alkaloids, saponins, polypeptides, and polysaccharides. Among them, oat alkaloids are the main anti-inflammatory actives, which can inhibit IKB kinase activity, thereby regulating pro-inflammatory cytokines and the COX-2 / PGE2 pathway; by blocking the activation of NF-κB in keratinocytes, they reduce the release of inflammatory factors (such as IL-1β, IL-8, and TNF-α), thereby alleviating skin redness, stinging, and inflammatory reactions; and by blocking histamine receptors, they reduce the transmission of pruritus signals at nerve endings, quickly relieving itching caused by contact dermatitis, eczema, etc.

[0057] The main active ingredients of gardenia fruit extract include iridoid glycosides (geniposide, genipin, hydroxyisogeniposide, geniposide acid), gardenia yellow pigments (crocin, crocin, etc.), organic acid esters (chlorogenic acid, quinic acid, geniposide, etc.), flavonoids (apigenin, luteolin, rutin, etc.), and triterpenoids (ursolic acid, etc.). The anti-inflammatory active ingredients of gardenia fruit extract are mainly geniposide and genipin. Geniposide can inhibit the release of inflammatory factors and increase the expression of anti-inflammatory factors by downregulating TLR4 expression, blocking the initiation of inflammatory signals; preventing NF-κB nuclear translocation, reducing the transcription of inflammatory genes (such as TNF-α, IL-6, COX-2); and thus alleviating skin inflammation and soothing sensitive skin. Genipin can induce glutathione S-transferase (GST) activity and the expression of GST-M1 and GST-M2 subunits, leading to the production of glutathione peroxidase (GSH-PX) under the catalysis of GST. This reaction scavenges oxygen ions and other free radicals in the body, inhibits lipid peroxidation, and reduces inflammatory damage caused by oxidative stress. Furthermore, gardenia fruit extract can competitively bind to inflammatory mediator receptors (such as NK-1) with substance P (a neuropeptide) through its polysaccharide structure, blocking the interaction between tachykinin and mast cells, reducing histamine release, and thus alleviating skin itching and inflammatory responses.

[0058] Hydrolyzed corn starch is a mixture of small-molecule dextrins and sugars obtained by enzymatic or acid treatment of corn starch. It can reduce mast cell degranulation, thereby inhibiting histamine release. Histamine is a key mediator in triggering itching and inflammation; reducing its release can significantly alleviate itching and inflammatory responses. Furthermore, stimulation of TRPV1 triggers the release of pro-inflammatory neuropeptides such as substance P (SP) and calcitonin gene-related peptide (CGRP), inducing pain or itching. Hydrolyzed corn starch can also reduce the expression of TRPV1 and increase the expression of CGRP, thereby reducing the transmission of nerve pain signals and exerting a nerve-sedative effect to achieve a soothing effect.

[0059] Kava root extract exerts its anti-inflammatory effects primarily through its active components, kavain. Kavain significantly inhibits NF-κB activation, preventing IκBα degradation and nuclear translocation of the p65 subunit. NF-κB is a key transcription factor whose activation promotes the expression of various inflammatory cytokines, such as TNF-α, IL-6, and iNOS. By inhibiting NF-κB activation, kavain significantly reduces the levels of these inflammatory cytokines, thereby alleviating the inflammatory response. Simultaneously, kavain inhibits the phosphorylation of MAPK (mitogen-activated protein kinase) family members, including JNK1 / 2, p38, and ERK1 / 2. These kinases play crucial roles in the inflammatory response; their activation leads to the production of inflammatory cytokines and cellular inflammatory responses. By inhibiting the activity of these kinases, kavain further reduces the expression of inflammatory cytokines, alleviating inflammation.

[0060] The anti-inflammatory effects of dragon's blood extract are primarily exerted through its active ingredient, procyanidins. It can also inhibit the nuclear translocation of the NF-κB p65 subunit and suppress the phosphorylation of MAPK (mitogen-activated protein kinase) family members, including JNK1 / 2, p38, and ERK1 / 2. These kinases play a crucial role in the inflammatory response; their activation leads to the production of inflammatory factors and cellular inflammatory reactions. By inhibiting the activity of these kinases, procyanidins A1 can further reduce the expression of inflammatory factors and alleviate inflammation. Procyanidins A1 can also activate Nrf2 (nuclear factor E2-related factor 2), thereby promoting the expression of HO-1 (heme oxygenase-1). Nrf2 is a transcription factor that regulates cellular antioxidant responses, while HO-1 is an important antioxidant enzyme that breaks down heme, producing metabolites with antioxidant and anti-inflammatory effects. By activating the Nrf2 / HO-1 pathway, procyanidins A1 can enhance cellular antioxidant capacity and reduce inflammatory damage caused by oxidative stress.

[0061] In summary, combining the above five plant-derived anti-inflammatory substances, provided they possess excellent anti-inflammatory effects, can serve as a candidate soothing and anti-inflammatory factor capable of achieving anti-inflammatory effects through multidimensional mechanisms.

[0062] Then, the present invention screens the components of the combination with the best soothing effect as the components of the soothing and anti-inflammatory factors by detecting the inhibition rate of hyaluronidase activity of combinations 1-10.

[0063] Hyaluronidase activity is associated with histamine release and inflammatory responses. Its hydrolysis of hyaluronic acid can trigger the release of histamine and inflammatory factors, leading to an inflammatory response that can exacerbate skin sensitivity (such as redness and itching). Therefore, ingredients capable of inhibiting hyaluronidase activity possess anti-inflammatory and soothing potential.

[0064] In this experiment, the inhibition rate of hyaluronidase activity by combinations 1-10 was determined using the hyaluronidase activity assay kit (540nm spectrophotometry) from Beijing Tianjingsha Gene Technology Co., Ltd.

[0065] The inhibition rate of hyaluronidase activity by combinations 1-10 was tested as follows: Figure 1 As shown. By Figure 1 It can be seen that combinations 1-10 all have a significant hyaluronidase inhibition effect compared with the blank control, that is, they all have anti-inflammatory potential and can be used as candidate soothing and anti-inflammatory factors for further optimization.

[0066] Preferably, in this embodiment, the combination with the strongest hyaluronidase activity inhibition rate is selected as the soothing and anti-inflammatory factor for further optimization and testing. The inhibition rates are ranked from largest to smallest as follows: combination 6 > combination 2 > combination 4 > combination 3 > combination 5 > combination 9 > combination 10 > combination 1 > combination 7 > combination 8. Combination 6 has the highest inhibition rate of 60.86% on hyaluronidase activity among the 10 combinations. Therefore, in this embodiment, combination 6—oat extract, gardenia fruit extract, hydrolyzed corn starch, 1,3-butanediol, 1,3-hexanediol, and water—is preferred as the main component of the soothing and anti-inflammatory factor, and further optimization and adjustment of the component ratios are made.

[0067] Furthermore, based on combination 6, this invention increases the proportion of one of the three active ingredients to form nine combinations (combinations 11-19, as shown in Table 2, where the proportions are volume ratios), in order to improve its inhibition rate on hyaluronidase activity.

[0068] Table 2 Optimization settings for the proportions of soothing and anti-inflammatory factors

[0069]

[0070] The inhibition rate of hyaluronidase activity of combinations 11-19 was tested according to the aforementioned method, and the results are as follows: Figure 2 As shown, the inhibition rates, arranged from largest to smallest, are: Combination 19 > Combination 13 > Combination 18 > Combination 16 > Combination 17 > Combination 12 > Combination 15 > Combination 11 > Combination 14. Combination 19 exhibits the highest inhibition rate against hyaluronidase activity.

[0071] Since the inhibitory effects of oat extract, gardenia fruit extract, and hydrolyzed corn starch extract on hyaluronidase activity are all dose-dependent (inhibition increases with increasing concentration), this invention also explored a combination of 10-20% oat extract, 10-20% gardenia fruit extract, and 10-20% hydrolyzed corn starch. Compared to combination 19, this combination further improved the inhibition rate of hyaluronidase activity, but the improvement was limited because the higher concentrations of oat extract, gardenia fruit extract, and hydrolyzed corn starch were not completely compatible, limiting the inhibitory effect of the combination on hyaluronidase activity. Considering solubility, inhibition rate, and cost, this invention ultimately determined combination 19 as the optimal ratio of soothing and anti-inflammatory factors and conducted a series of subsequent efficacy tests.

[0072] Cellular anti-inflammatory assay of soothing and anti-inflammatory factors: RAW264.7 macrophages with well-confluent monolayers were selected from 96-well plates. The culture medium in the 96-well plates was discarded. Soothing and anti-inflammatory factor samples prepared in a 1:1:9 ratio were diluted to a non-cytotoxic concentration for testing. For the sample group, 1%, 2%, and 5% soothing and anti-inflammatory factors and LPS were added to each well; for the model control group, LPS-containing cell culture medium was added to each well; for the positive control group, dexamethasone sodium phosphate and LPS-containing cell culture medium was added to each well; and for the blank control group, cell culture medium was added to each well. 100 μL of cell culture medium was added to each well, with 6 wells in each group. After sample addition, the 96-well plates were incubated at 37℃ in a 5% CO2 incubator for (24±2) h. After incubation, the supernatant was collected to determine the relative levels of three inflammatory factors—tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and interleukin-1β (IL-1β)—as well as the inflammatory mediator NO.

[0073] Inflammatory factor assay: The levels of TNF-α, IL-6, and IL-1β were measured according to the ELISA kit instructions, and the downregulation rate was calculated. The formula is: Downregulation rate = (1 - T / C) × 100%, where T refers to the average level of inflammatory factors in the sample group, and C refers to the average level of inflammatory factors in the model control group.

[0074] NO relative content assay: 50 μL of cell culture supernatant was collected from each well and thoroughly mixed with 50 μL of Griess reagent. The mixture was reacted in the dark for 10 min, and the A value was detected at 540 nm using a microplate reader. The results were recorded and corrected using a blank control group. The corrected values ​​were used to calculate the relative NO content and relative NO inhibition rate. The formulas are: Relative NO content = A sample / AC × 100%; Relative NO inhibition rate = (AC - A sample) / AC × 100%, where A sample refers to the mean A value of the corrected sample group, and AC is the mean A value of the corrected model control group.

[0075] Figure 3-5The results showed that the levels and downregulation rates of three inflammatory factors and the relative levels of the inflammatory mediator NO were presented. The results showed that after LPS induction, the levels of inflammatory factors and the relative levels of NO in the RAW264.7 strain were significantly higher than those in the blank control group (P<0.05), proving that the experimental model was valid.

[0076] Compared with the model control group, the soothing and anti-inflammatory factors significantly reduced the levels of three inflammatory factors. The downregulation rates of TNF-α by 1%, 2%, and 5% of the soothing and anti-inflammatory factors were 28.29%, 34.92%, and 44.43%, respectively; the downregulation rates of IL-6 were 32.17%, 42.53%, and 55.11%, respectively; and the downregulation rates of IL-1β were 35.87%, 43.10%, and 52.82%, respectively. The results demonstrate that the soothing and anti-inflammatory factors can significantly reduce the levels of inflammatory factors and have a dose-response effect (P<0.05).

[0077] Compared with the model control group, the soothing and anti-inflammatory factors significantly reduced the relative content of the inflammatory mediator NO. The relative inhibition rates of 1%, 2%, and 5% soothing and anti-inflammatory factors against NO were 42.72%, 63.02%, and 74.38%, respectively, increasing with increasing concentration. The results demonstrate that the soothing and anti-inflammatory factors can significantly reduce the relative content of inflammatory mediators and exhibit a dose-response effect (P<0.05).

[0078] Cellular testing showed that the soothing and anti-inflammatory factors can reduce the levels of inflammatory factors and mediators in cells, proving that the soothing and anti-inflammatory factors have anti-inflammatory and soothing effects.

[0079] The effects of soothing and anti-inflammatory factors on reducing redness and relieving itching in humans: 1% histamine solution and 5% soothing and anti-inflammatory factor solution were prepared. First, the 1% histamine solution was applied to the inner forearm to stimulate the skin for 20 minutes. Then, the 5% soothing and anti-inflammatory factor solution was applied to the same location. Skin reactions were recorded by taking pictures at 20 minutes and 30 minutes. The control group did not receive any treatment.

[0080] The results are as follows Figure 6 As shown, after 20 minutes of stimulation with 1% histamine solution, significant erythema and large-area wheals appeared on the skin, indicating a stress response. After 20 minutes of soothing and anti-inflammatory factor solution, the wheals almost disappeared, the erythema significantly faded, and itching completely stopped. In contrast, the untreated control group still had severe erythema, the wheals hardly decreased, and the itching was significant. After 30 minutes of soothing and anti-inflammatory factor solution, the wheals disappeared completely, and the erythema almost disappeared. In contrast, the wheals in the untreated control group disappeared by more than half, but the erythema remained severe.

[0081] The results showed that the soothing and anti-inflammatory factors had a significant effect on improving histamine-induced erythema and itching, and could soothe the skin, quickly reduce redness and relieve itching.

[0082] To test whether the soothing and anti-inflammatory factors have an anti-allergic effect, one control group and two experimental groups were set up. The control group used only 0.1% histamine solution, while the experimental groups used a mixture of 0.1% histamine and 2% soothing and anti-inflammatory factors, and a mixture of 0.5% histamine and 2% soothing and anti-inflammatory factors, respectively. All three solutions were applied to the inner forearm, and skin reactions were recorded by photographing after 30 minutes.

[0083] The results are as follows Figure 7 As shown, after stimulating the skin with a 0.1% histamine solution for 30 minutes, obvious erythema and a few wheals appeared, indicating a stress response in the skin. After stimulating the skin with a mixture of 0.1% histamine and 2% soothing anti-inflammatory factors for 30 minutes, the histamine showed no significant irritation. After stimulating the skin with a mixture of 0.5% histamine and 2% soothing anti-inflammatory factors for 30 minutes, erythema appeared, but no wheals were observed.

[0084] The results showed that 2% soothing and anti-inflammatory factors could significantly reduce the irritation of histamine on the skin, have a significant anti-allergic effect, and effectively resist external stimuli.

[0085] Based on the aforementioned soothing and anti-inflammatory factors, this invention provides an anti-allergic and soothing composition comprising: phase A, phase B, phase C, phase D, and phase E, in volume parts as follows:

[0086] Phase A consists of 80-90 parts water, 0.01-0.05 parts EDTA-2Na, and 0.1-0.4 parts Carbopol 941;

[0087] Phase B includes 0.01-0.1 parts sodium hyaluronate and 2-4 parts 1,3-butanediol;

[0088] Phase C includes 0.1-0.4 parts of arginine;

[0089] Phase D includes 0.1-0.4 parts of p-hydroxyacetophenone and 1-3 parts of 1,3-butanediol;

[0090] Phase E includes 0.5-1.5 parts glycerol glucoside, 3-7 parts soothing and anti-inflammatory factors, and 0.5-1.5 parts preservatives.

[0091] The preparation method of the above-mentioned anti-allergic and soothing composition includes the following steps.

[0092] S1. Heat phase A to 80-85℃ and stir to dissolve.

[0093] S2. After phase A cools down to 55°C, add the well-dispersed phase B to phase A and stir to cool down.

[0094] S3. Add phase C to the mixture from step S2 to adjust the pH, and stir until homogeneous.

[0095] S4. Heat phase D to 50°C under controlled temperature, stir to dissolve, and then add it to the mixture from step S3, stirring.

[0096] S5. After the mixture from step S4 has cooled to about 42°C, add the raw materials of phase E in sequence and stir evenly.

[0097] The anti-allergic and soothing composition of the present invention will be described in detail below with reference to specific embodiments and accompanying drawings.

[0098] Example 1

[0099] This embodiment provides an anti-allergic and soothing composition, the formulation of which is shown in Table 3. Its preparation method is as follows:

[0100] S1. Heat phase A to 80-85℃ and stir to dissolve.

[0101] S2. After phase A cools down to 55°C, add the well-dispersed phase B to phase A and stir to cool down.

[0102] S3. Add phase C to the mixture from step S2 to adjust the pH to 6.0-7.0, and stir until homogeneous.

[0103] S4. Heat phase D to 50°C under controlled temperature, stir to dissolve, and then add it to the mixture from step S3, stirring.

[0104] S5. After the mixture from step S4 has cooled to about 42°C, add the raw materials of phase E in sequence and stir evenly.

[0105] Table 3. Formulation of anti-allergic and soothing composition

[0106]

[0107] Test case

[0108] Yam is the rhizome of a plant in the Dioscoreaceae family. The skin of yam contains saponins and calcium oxalate crystals, which can irritate nerve endings, leading to dry, burning, and itchy skin. The plant alkaloids in the mucus are also irritating and can directly stimulate nerve endings in the skin, causing discomfort such as itching and redness. Using yam as an irritant, this study tested whether an anti-allergic and soothing composition prepared from soothing and anti-inflammatory factors had a redness-reducing and itching-relieving effect.

[0109] like Figure 8 As shown, a small piece of yam peel was applied to the inside of the forearm for 5 minutes, and then the anti-allergy and soothing composition was applied to the irritated area. After 30 minutes, the skin reaction was recorded by taking a picture.

[0110] Five minutes after yam irritated the skin, obvious erythema and intense itching appeared, indicating a stress response. Applying the anti-allergy soothing composition to the skin for 30 minutes eliminated the itching, and the erythema subsided after one hour. In contrast, the control group, which did not use the anti-allergy soothing composition, still showed obvious erythema and intense itching.

[0111] The results showed that the anti-allergic and soothing composition prepared from soothing and anti-inflammatory factors had a significant soothing effect, could quickly reduce redness and relieve itching, and resist external stimuli.

[0112] In summary, this invention provides an anti-allergic and soothing composition containing soothing and anti-inflammatory factors. The three main active ingredients work synergistically to exert their effects at different stages of the inflammatory pathway: oat extract and gardenia fruit extract inhibit the activation of core inflammatory factors such as NF-κB, reducing inflammation at its source; genipin from oat alkaloids and gardenia fruit extract are potent antioxidants that neutralize the large number of free radicals generated during inflammation, preventing the spread of inflammation; and hydrolyzed corn starch reduces histamine release, thereby alleviating skin itching and inflammatory responses, and inhibits TRPV1 receptors, rapidly reducing burning and stinging sensations.

[0113] In addition, oat extract and gardenia fruit extract, as plant-derived anti-allergic ingredients, possess multi-target, synergistic, high safety, and multi-effect properties. For example, the β-glucan in oat extract contains a large number of hydrophilic groups, which can absorb and lock in moisture in the stratum corneum, promote collagen synthesis by fibroblasts, thereby enhancing the skin's moisturizing ability and improving problems such as dryness and peeling. Oat protein and high-quality oils can form a breathable protective film on the skin surface, effectively reducing moisture evaporation, increasing the moisture content of the stratum corneum, providing long-lasting hydration, and playing a role in moisturizing and stabilizing the skin.

[0114] In addition, the β-glucan and lipid components of oat extract can promote the expression of epidermal barrier proteins, replenish intercellular matrix, accelerate the repair of damaged barriers, and reduce transepidermal water loss, thus playing a role in repairing the skin barrier.

[0115] Therefore, the anti-allergy and soothing composition containing the soothing and anti-inflammatory factors of this invention is more comprehensive and gentler as a skin care product when combating complex and chronic sensitive skin problems, and shows great potential in terms of safety, tolerability and overall skin health maintenance in long-term skin care.

[0116] The embodiments described above are merely examples of several implementations of the present invention, and while the descriptions are relatively specific and detailed, they should not be construed as limiting the scope of the invention. It should be noted that those skilled in the art can make various modifications and improvements without departing from the concept of the present invention, and these modifications and improvements all fall within the scope of protection of the present invention.

Claims

1. An anti-irritant soothing composition characterized in that, Comprise by volume parts: The A phase comprises 80-90 parts of water, 0.01-0.05 parts of EDTA-2Na, 0.1-0.4 parts of Carbopol 941; The B phase comprises 0.01-0.1 parts of sodium hyaluronate, 2-4 parts of 1,3-butanediol; The C phase comprises 0.1-0.4 parts of arginine; The D phase comprises 0.1-0.4 parts of p-hydroxyacetophenone, 1-3 parts of 1,3-butanediol; The E phase comprises 0.5-1.5 glycerol glucoside, 3-7 parts of soothing anti-inflammatory factor, 0.5-1.5 parts of preservative; The soothing anti-inflammatory factor comprises oat extract, gardenia fruit extract, and hydrolyzed corn starch. The volume parts of the oat extract, gardenia fruit extract, and hydrolyzed corn starch in the soothing anti-inflammatory factor are 5-20 parts, 5-20 parts, and 5-20 parts, respectively.

2. The anti-irritant soothing composition according to claim 1, characterized in that: The preparation method of the oat extract comprises: taking oat powder, extracting with a 45-55℃ solvent for 1.5-3h, centrifuging, ultrafiltering, and concentrating to obtain the oat extract, wherein the solvent is water, a mixture of water and glycerol, or a mixture of water and butanediol.

3. The anti-irritant soothing composition according to claim 1, characterized in that, The preparation method of the gardenia fruit extract comprises: crushing gardenia fruit, adding 10-15 times the volume of water, ultrasonically extracting at 50-70℃ for 30-60 minutes, filtering, and concentrating to obtain the gardenia fruit extract.

4. The anti-irritant soothing composition according to claim 1, characterized in that, The preparation method of the hydrolyzed corn starch comprises: sequentially using heat-resistant α-amylase and glucoamylase to hydrolyze corn starch, then heating to inactivate the enzymes, decolorizing, and filtering to obtain the hydrolyzed corn starch.

5. Process for the preparation of an anti-irritation soothing composition according to any one of claims 1 to 4, characterized in that: Sequentially comprising the following steps: S1, heating the A phase to 80-85℃ and stirring to dissolve; S2, after the A phase is cooled to 55℃, adding the dispersed B phase to the A phase and stirring uniformly; S3, adding the C phase to the mixture of step S2 and stirring uniformly; S4, heating the D phase to 50℃, stirring to dissolve, and then adding to the mixture of step S3 and stirring; S5, after the mixture of step S4 is cooled to 41-43℃, sequentially adding each raw material of the E phase and stirring uniformly.

6. The use of the anti-allergic soothing composition according to any one of claims 1-4 in the preparation of skin care products.

7. Use according to claim 6, characterized in that, The skin care products comprise skin softener, skin jelly, skin emulsion, skin cream, essence, mask, and spray.

Images